Navidea Biopharmaceuticals, Inc.
NAVBDelisted Jan 16, 2024- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0000810509
Navidea Biopharmaceuticals, Inc. was delisted on Jan 16, 2024; its insiders filed their last Form 4 on Dec 5, 2023; 24 institutions reported holding it in 13F filings for Q3 2023, worth $225.8K in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Navidea Biopharmaceuticals, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Navidea Biopharmaceuticals, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Scott John K Jr. | Director, 10% Owner | 0 | Dec 5, 2023 | 0 |
| Stefanelli Jill | Director | 941,667 | Nov 20, 2023 | 0 |
| Moss Dana J | Director | 866,667 | Nov 20, 2023 | 0 |
| Dais Craig | CHIEF FINANCIAL OFFICER | 973,633 | Nov 14, 2023 | 0 |
| Cappello Alexander L | Director | 67,727 | Nov 30, 2022 | 0 |
| Wilson Joshua M. | Director | 30,000 | Nov 30, 2022 | 0 |
| Witter Malcolm G | Director | 165,138 | Nov 30, 2022 | 0 |
| Bhalla Amit | Director | 71,818 | Nov 30, 2022 | 0 |
| Rosol Michael Stanley | Chief Medical Officer | 55,725 | Sep 13, 2022 | 0 |
| Farb Thomas F | Director | 33,425 | Dec 2, 2021 | 0 |
| Winkler Agnieszka | Director | 33,600 | Dec 2, 2021 | 0 |
| Mikhail Michel | Chief Regulatory Officer | – | Dec 2, 2021 | 0 |
| Bruck Claudine | Director | 16,519 | Jul 7, 2021 | 0 |
| Rouan Sarah Kathryn | Director | 18,242 | Jul 7, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 15, 2023 (view filing) | Jun 1 | 14 daysLate | Scott John K Jr.Director, 10% Owner | PPurchase | +11.5M | $0.104 | +$1.20M | –12.0K after | Derivative |
| Sep 1, 2022 (view filing) | Aug 30 | 2 days | Witter Malcolm GDirector | PPurchase | +511.1K | – | – | –115 after | Derivative2 lots |
| Sep 1, 2022 (view filing) | Aug 30 | 2 days | Scott John K Jr.Director, 10% Owner | SSale | −2.17M | $1.10 | −$2.40M | –0 after | Derivative |
| Sep 1, 2022 (view filing) | Aug 30 | 2 days | Scott John K Jr.Director, 10% Owner | PPurchase | +10.7M | – | – | –2.40K after | Derivative2 lots |
| May 3, 2022 (view filing) | Apr 10 | 23 daysLate | Scott John K Jr.Director, 10% Owner | PPurchaseSeries G Redeemable Preferred Stock | +3.26K | – | – | New position3.26K after | |
| May 3, 2022 (view filing) | Apr 10 | 23 daysLate | Scott John K Jr.Director, 10% Owner | SSale | −2.17M | $0.0529 | −$115.0K | –0 after | Derivative |
| May 3, 2022 (view filing) | Apr 10 | 23 daysLate | Scott John K Jr.Director, 10% Owner | PPurchase | +2.17M | $0.0006 | +$1.39K | –1.74K after | Derivative |
| Sep 17, 2021 (view filing) | Sep 17 | Same day | Witter Malcolm GDirector | PPurchase | +20.0K | $1.60 | +$32.0K | +25.6%98.3K after | |
| Jul 26, 2021 (view filing) | Jul 26 | Same day | Witter Malcolm GDirector | PPurchase | +15.0K | $1.70 | +$25.5K | +23.7%78.3K after |